These innovative therapies , Tirzepatide , represent a significant advancement in managing metabolic dysfunction and possibly related disorders. These drugs are categorized as GLP-1 receptor agonists , indicating these substances to replicate the endogenous GLP-1 peptide, stimulating metabolic secretion and suppressing hunger . Despite Semaglutide